• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Shannon Ellis

Articles by Shannon Ellis

Biologics make some inroads, but generics still clog CFDA

March 19, 2014
By Shannon Ellis
SHANGHAI – The Center for Drug Evaluation (CDE) of the China Food and Drug Administration (CFDA) has released its annual report for 2013 which reveals only small gains have been made to fix the slow and overcrowded approval process.
Read More

Late-stage drug companies take more than half of China’s venture capital pie

March 18, 2014
By Shannon Ellis

SHANGHAI – In 2013, venture capital (VC) activity in China’s life sciences sector remained strong, dipping only slightly below the year previous. Investor enthusiasm did not diminish even when China barred companies from holding initial public offerings (IPO) here, the exit of choice for VCs.


Read More

China's new simplified M&A rules: Not so simple, but a positive step

March 13, 2014
By Shannon Ellis

China’s new simplified M&A rules a step in the right direction

March 12, 2014
By Shannon Ellis
SHANGHAI – After a year of revisions, China’s Ministry of Commerce (MOFCOM) revealed its anticipated new “simple rules” for mergers and acquisitions. The move signals the government’s intentions toward fast-tracking deals that don’t trigger competition issues, but with the caveat that certain conditions apply.
Read More

TCM benefits from better science, but innovation still hamstrung by tradition

March 12, 2014
By Shannon Ellis
SHANGHAI – Bayer AG’s recent purchase of traditional Chinese medicine (TCM) maker Dihon Pharmaceutical Group Co. was viewed by some as a step closer to the legitimization of the TCM drug market, one that occupies about a third to a half of all revenues here.
Read More

Biotech – fastest growing sector in health care – stands out as a key opportunity

March 11, 2014
By Shannon Ellis

SHANGHAI – China continues to entice and confound those looking for the right opportunity to invest in its rapidly changing health care sector. At the 5th China Healthcare Investment Conference held in Shanghai, biotech stood out as the key opportunity among numerous strategies discussed.


Read More

Bayer buys into China’s lucrative TCM market

March 5, 2014
By Shannon Ellis
SHANGHAI – Bayer AG is buying Dihon Pharmaceutical Group Co. located China’s southwest Yunnan province. Privately held Dihon makes OTC and traditional Chinese medicines (TCM) sold in China and Southeast Asia.
Read More

Chinese authorities list New Year’s resolutions

March 5, 2014
By Shannon Ellis
HONG KONG – After a rocky year for many biopharma companies in China hit hard by bribery investigations companies may find some hopeful points in the overall trend of stricter supervision and punishment in the government’s list of priorities for health care enforcement.
Read More

China’s Taxus Pharma buys Cardium to get a foothold in regenerative medicine

March 5, 2014
By Shannon Ellis
SHANGHAI – Privately held Shanxi Taxus Pharmaceuticals Co. Ltd., a subsidiary of Shenzhen Forntsea Taxus Industry Capital Management, will acquire majority shares in innovative drug developer Cardium Therapeutics Inc. (CRXM), of San Diego, for $5 million in cash.
Read More

The Chinese whistleblower – friend or foe? Monetary gain can be a distraction

Feb. 26, 2014
By Shannon Ellis
SHANGHAI – In the summer of China’s pharma scandal there was one constant: whistleblowers and their allegations of corruption backed by insider knowledge.
Read More
Previous 1 2 … 56 57 58 59 60 61 62 63 64 … 68 69 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 30, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe